APOMAB
18 Jun 2020
Trial Summary
The purpose of this study is to determine if APOMAB, (an imaging agent which is an antibody with a small amount of radiation attached to it) which has been designed to detect tumour cell death, is safe and tolerable to use in humans.
Acronym:
APOMAB
ACTRN/NCT /ethics:
ACTRN12620000622909
Scientific title:
This trial is a phase 1, single-centre, open label, single-dose study of 89Zr-APOMAB using PET/CT imaging in a series of 18 participants who are known to have inoperable stage III or stage IV non-small cell lung cancer (NSCLC), or limited or extensive stage small cell lung cancer (SCLC), or FIGO stage IV grade 3 serous papillary Ovarian Cancer.
Trial & Patient Characteristics
| Cancer Type | Gynaecological, Lung & Mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18+ years |
| Sex | All |
| Tumour Stream | Lung or Ovarian Cancer |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2020-06-01 |
| Anticipated End Date | 2021-12-31 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |